On Tuesday, United Therapeutics Corporation (NASDAQ:UTHR)’s shares declined -5.17% to $163.31.
United Therapeutics Corporation (UTHR) declared its financial results for the first quarter ended March 31, 2015. Martine Rothblatt, Ph.D., United Therapeutics’ Chairman and Co-Chief Executive Officer stated that their total revenues rose as contrast to the preceding year and they are ongoing to see a growing number of patients being prescribed their pulmonary arterial hypertension (PAH) products. Since its commercial launch last June, Orenitram® is being prescribed to an increasing number of patients and this momentum underscores their belief in the growing clinical support for the use of their orally-administered prostacyclin analogues.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH).
CIT Group Inc. (NYSE:CIT)’s shares dropped -5.16% to $44.85.
CIT Group Inc. (CIT) declared that its Board of Directors has declared a quarterly cash dividend of $0.15 per common share on its outstanding common stock. The common stock dividend is payable on May 29, 2015 to common shareholders of record as of May 15, 2015.
CIT Group Inc. operates as the holding company for CIT bank that provides commercial financing and leasing products; and a suite of savings options in the United States. Its Transportation & International Finance segment offers leasing and financing solutions to operators and suppliers in the aviation and railcar industries.
At the end of Tuesday’s trade, National-Oilwell Varco, Inc. (NYSE:NOV)‘s shares dipped -5.05% to $51.93.
National-Oilwell Varco, Inc. (NOV) stated that for its first quarter ended March 31, 2015, it earned net income of $310 million, or $0.76 per fully diluted share, contrast to fourth quarter ended December 31, 2014 net income of $595 million, or $1.39 per fully diluted share. Not taking into account other items of $122 million in pre-tax charges related to an early retirement program, $9 million of Venezuela asset write-down, and $69 million of non-recurring foreign tax exposure, net income was $466 million, or $1.14 per fully diluted share, down 33 percent from the fourth quarter of 2014, and down 12 percent from the first quarter of 2014, not taking into account other items from all periods.
National Oilwell Varco, Inc. designs, manufactures, and sells equipment and components used in oil and gas drilling, completion, and production; and provides oilfield services to the upstream oil and gas industry worldwide.
Scorpio Bulkers Inc (NYSE:SALT), ended its Tuesday’s trading session with -2.33% loss, and closed at $2.51.
Scorpio Bulkers Inc (SALT) declared that it has reached agreements to sell two Capesize newbuilding dry bulk vessels and an Ultramax newbuilding dry bulk vessel for about $111 million in aggregate.
The Capesize vessels are presently being constructed in China and South Korea, and have predictable delivery dates between the third quarter of 2015 and the second quarter of 2016. The Ultramax vessel is presently being constructed in China and has an predictable delivery date in the first quarter of 2016.
Scorpio Bulkers Inc., together with its auxiliaries, engages in the marine transportation of dry bulk commodities. Its fleet transports a range of major and minor bulk commodities, counting ores, coal, grains, and fertilizers along worldwide shipping routes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
